Day 1 recordPCAC favorable

Peptide dossier / July 23–24, 2026

MOTS-c

The scientific premise is mitochondrial and metabolic, but FDA said it found no clinical study or human-administration evidence and no adequate nonclinical toxicity package.

Read the verdict Hear the testimony

free base7–5–2Yes · No · Abstain · n=14Recorded at 11:33:43.680 acetate7–5–2Yes · No · Abstain · n=14Recorded at 11:38:51.840

Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.

Editorial review

The central tension in this record.

FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.

Evidence signal01

The biological premise is scientifically substantive

FDA reviewed mitochondrial signaling and rodent metabolic findings. These are legitimate research inputs, not fabricated claims or mere marketing copy.

FDA briefing pp. 25–27

Decisive limitation02

No administered-human bridge was identified

The record did not show whether injected MOTS-c reaches active concentrations in people, what dose is relevant or what the human safety profile looks like.

FDA briefing pp. 27–33

PeptideBase read

The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.

The case made in the room

Named speakers. Their strongest argument. Then the record check.

These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.

2named speaker moments

100%recording checked

Only named, source-reconciled speaker moments that were checked against the recording appear here. Statements remain attributed arguments unless the underlying evidence was independently established; no machine-caption wording is published as a quotation.

01Supports listing

Pinchas “Hassy” Cohen, MD

Dean, USC Leonard Davis School of Gerontology; investigator whose lab first described MOTS-c

Verify credentials

Attributed testimony

The discovery-science case

Cohen identified himself as the dean of USC’s gerontology school and said MOTS-c was discovered in his laboratory. He described it as a mitochondria-encoded metabolic regulator and summarized preclinical work involving metabolism, muscle biology and age-related decline.

MOTS-c session · discovery and preclinical evidenceAudio-checked paraphrasePlay the source10:08:27–10:09:39

02Opposes listing

Peter Lurie, MD, MPH

President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner

Verify credentials

Attributed testimony

The hearing-wide case against all seven

Lurie said CSPI opposed adding all seven substances. He argued that the FDA criteria had not been met, that compounded products could create consumer risks, and that listing could weaken incentives for development through the standard drug-approval pathway.

Opening public hearing · explicitly applied to all seven substancesAudio-checked paraphrasePlay the source00:57:09–00:57:55

Claim-specific check

Discovery science and endogenous mitochondrial biology support clinical interest in MOTS-c.

Discovery, animal and association evidence

What supports it

Cohen described the peptide’s discovery and preclinical metabolic and muscle findings. Endogenous levels and human associations are not evidence of what an administered compounded product does.

FDA’s answer

FDA identified no human-administration studies and found a lack of evidence to evaluate effectiveness for the nominated uses.

FDA Day 1 presentation · 10:59:54

PeptideBase assessment

The discovery record is scientifically important. It does not establish effectiveness, dose or safety after exogenous administration to people.

Why the judgments diverged

Promising endogenous biology did not answer the administration question.

The favorable majority appears to have found the discovery science and biological rationale sufficient for a positive recommendation. FDA separated endogenous occurrence and preclinical promise from evidence about administering a compounded MOTS-c product to people.

Editorial inference from the hearing record—not an attributed rationale for every voter

Claim versus record

What the official material supports—and what it does not.

These are recurring propositions in the wider peptide discussion, not attributed speaker quotations.

Human relevance

Recurring claim

Human genetic associations show injected MOTS-c works in people.

Official record

FDA reviewed mechanistic and association-based material but said it found no clinical studies evaluating administration of MOTS-c to humans.

What it does not establish

Human association data and endogenous biology do not establish the pharmacology, dose response, safety or effectiveness of an injected exogenous product.

FDA briefing pp. 25–30

Exposure

Recurring claim

Injected MOTS-c will remain intact long enough to reach active concentrations.

Official record

FDA cited an in-vitro study reporting rapid hydrolysis in human blood and said it remained unknown whether exogenous administration could generate pharmacologically active concentrations over time.

What it does not establish

The in-vitro result raises an exposure question; it does not by itself prove clinical inactivity.

FDA briefing pp. 25–27

Evidence architecture

Eight questions applied consistently.

“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.

Evidence questions applied to MOTS-c, with FDA’s record summary and a locator.
Evidence question	Status	FDA-record summary	Locator
Human clinical evidence	absent	FDA said it identified no human-administration clinical studies.	Briefing pp. 27–30
Nonclinical evidence	indirect	Rodent metabolic pharmacology was reviewed, but FDA said its clinical relevance was unknown.	Briefing pp. 25–30
Exact-form match	limited	The record did not establish a complete clinical evidence package for free base or acetate.	Briefing pp. 6–18
Nominated-route match	absent	The nomination proposed SC injection; FDA identified no human administration evidence.	Briefing pp. 6, 27–30
Evaluated-use match	contested	FDA’s event page and substance briefing describe the scope differently; both descriptions must remain visible.	Event page; briefing pp. 6, 30
Product characterization	limited	FDA considered both forms not well characterized.	Briefing pp. 7–18
Human safety	absent	No clinical exposure data were identified, and FDA found no adequate acute, repeat-dose, genotoxicity, reproductive or carcinogenicity studies.	Briefing pp. 25–29
Historical compounding use	limited	FDA found the extent of historical use in compounding unknown.	Briefing pp. 18–23

Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation

FDA findings

Five parts of the staff case.

01characterizationBoth MOTS-c free base and MOTS-c acetate were considered not well characterized.Day 1 pp. 131, 134
10:54:02 02effectivenessFDA found a lack of evidence to evaluate effectiveness for the nominated uses and identified no human-administration studies.Day 1 p. 138
10:59:54 03safetyFDA found a lack of clinical and nonclinical safety information.Day 1 pp. 139–143
11:02:47 04historical useFDA found the extent of historical use in compounding unknown.Day 1 pp. 144–147
11:04:39 05recommendationFDA proposed that neither MOTS-c free base nor MOTS-c acetate be included on the 503A Bulks List.Day 1 pp. 147–148
11:06:02

What changes the assessment

Open evidence gaps and direct sources.

A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.

Human-administration trials with pharmacokinetics and dose response

Acute, repeat-dose, genetic, reproductive and carcinogenicity testing

Resolved hearing scope plus exact form and finished-product specifications